Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children with Hematoplastic Disease

Last updated: March 25, 2025
Sponsor: Wei Zhao
Overall Status: Active - Recruiting

Phase

4

Condition

Hematologic Neoplasms

Treatment

Anti-Infective Drugs

dasatinib

Eltrombopag

Clinical Study ID

NCT03844360
Antineoplastic Drugs001
  • Ages 1-18
  • All Genders

Study Summary

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients must be diagnosed with hematological neoplasms

  • Antineoplastic drugs or anti-infective drugs used as part of regular treatment

Exclusion

Exclusion Criteria:

  • expected survival time less than the treatment cycle;

  • patients with other factors that researcher considers unsuitable for inclusion.

Study Design

Total Participants: 1500
Treatment Group(s): 7
Primary Treatment: Anti-Infective Drugs
Phase: 4
Study Start date:
January 31, 2016
Estimated Completion Date:
December 31, 2026

Study Description

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs based on the opportunistic sampling strategy in children with confirmed or suspected hematological neoplasms.

Connect with a study center

  • Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu 221000
    China

    Completed

  • State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Tanjin, Tianjin 300020
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.